Healthcare / Medical DistributionWarsaw
$728.00
-7.00 (-0.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $194.1M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
19.0x
↓EV/EBITDA
9.2x
↓ROE
14.7%
↑Gross Margin
11.4%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
+18.5%
FCF margin
3.1%
FCF / Net income
2.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.64B · net income $155.6M · FCF $424.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.64B | $13.64B | $12.61B | $11.81B | $11.23B |
| Net Income | $155.6M | $155.6M | $154.2M | $146.3M | $137.2M |
| EBITDA | $392.6M | $392.6M | $417.9M | $399.7M | $349.9M |
| EPS | — | — | 34.01 | 32.48 | 30.00 |
| Gross Margin | 11.4% | 11.4% | 11.4% | 11.1% | 10.0% |
| Operating Margin | 2.2% | 2.2% | 2.4% | 2.3% | 2.3% |
| Net Margin | 1.1% | 1.1% | 1.2% | 1.2% | 1.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.39 | 0.37 | 0.43 |
| Current Ratio | 0.90 | 0.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $424.0M | $424.0M | $-29.7M | $194.1M | $254.5M |
| Returns | |||||
| ROE | 14.7% | 14.7% | 13.5% | 14.8% | 15.5% |
| Valuation | |||||
| P/E | 19.05 | 19.05 | 25.73 | 26.54 | 22.37 |
| EV/EBITDA | 9.15 | 9.15 | 10.31 | 10.37 | 9.26 |
| P/B | 3.05 | 3.05 | 3.48 | 3.92 | 3.48 |
| Growth & Yield | |||||
| Revenue Growth | 8.2% | 8.2% | 6.8% | 5.2% | — |
| EPS Growth | — | — | 4.7% | 8.3% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.4%
Start / end P/E
n/dx → n/dx
EPS bridge
34.01 → n/d
Residual
+4.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.